MC
KLDO

Menta Capital’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Menta Capital’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$164K Buy
+14,136
New +$206K 0.07% 416

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Menta Capital's KLDO Position: Q2 2019 in Review

Menta Capital opened a new position in Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2019: 14,136 shares worth $164K. The stake represents 0.07% of the portfolio and ranks #416 among its holdings.

37 funds tracked by Wall St. Rank hold KLDO as of Q2 2019.

  • Menta Capital held 14,136 shares of Kaleido Biosciences, Inc. Common Stock worth $164K as of Q2 2019.
  • Kaleido Biosciences, Inc. Common Stock was a new Menta Capital position in Q2 2019.
  • Kaleido Biosciences, Inc. Common Stock made up 0.07% of Menta Capital's portfolio in Q2 2019, its #416 holding.
  • 37 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.